Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Regional variation i användningen av TTF vid glioblastombehandling

Kinhult, Sara LU ; Tavelin, Björn ; Löfgren, David ; Rosenlund, Lena ; Sandström, Maria ; Strandeus, Michael and Henriksson, Roger (2023) In Lakartidningen 120.
Abstract

The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide. Based on a randomised trial, showing five months increased survival, TTF has been introduced in the management of patients with good performance status. Data from the Swedish national quality registry for CNS tumours have been analysed for TTF usage. The results demonstrate that 65 percent of the patients accepted treatment with TTF. More than half of the treated patients interrupted treatment due to low compliance or their own wish. Median treatment time was 164 days, with a range from 0 to 774 days. There was a large variation between different regions in how many patients were offered TTF treatment. A non-significant... (More)

The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide. Based on a randomised trial, showing five months increased survival, TTF has been introduced in the management of patients with good performance status. Data from the Swedish national quality registry for CNS tumours have been analysed for TTF usage. The results demonstrate that 65 percent of the patients accepted treatment with TTF. More than half of the treated patients interrupted treatment due to low compliance or their own wish. Median treatment time was 164 days, with a range from 0 to 774 days. There was a large variation between different regions in how many patients were offered TTF treatment. A non-significant trend to better survival was seen for the group of TTF-treated patients compared to individually matched controls. In summary, TTF is a new treatment for glioblastoma, with potential to prolong survival also in real world patients. Today, the treatment is not offered equally to all patients, despite national guidelines.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
alternative title
Regional variation in usage of TTF (Optune)
publishing date
type
Contribution to journal
publication status
published
subject
in
Lakartidningen
volume
120
publisher
Swedish Medical Association
external identifiers
  • pmid:37401252
  • scopus:85164005813
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
25a4a995-8317-400e-b971-633f0b26302c
date added to LUP
2023-09-05 15:18:46
date last changed
2025-04-20 13:23:53
@article{25a4a995-8317-400e-b971-633f0b26302c,
  abstract     = {{<p>The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide. Based on a randomised trial, showing five months increased survival, TTF has been introduced in the management of patients with good performance status. Data from the Swedish national quality registry for CNS tumours have been analysed for TTF usage. The results demonstrate that 65 percent of the patients accepted treatment with TTF. More than half of the treated patients interrupted treatment due to low compliance or their own wish. Median treatment time was 164 days, with a range from 0 to 774 days. There was a large variation between different regions in how many patients were offered TTF treatment. A non-significant trend to better survival was seen for the group of TTF-treated patients compared to individually matched controls. In summary, TTF is a new treatment for glioblastoma, with potential to prolong survival also in real world patients. Today, the treatment is not offered equally to all patients, despite national guidelines.</p>}},
  author       = {{Kinhult, Sara and Tavelin, Björn and Löfgren, David and Rosenlund, Lena and Sandström, Maria and Strandeus, Michael and Henriksson, Roger}},
  issn         = {{0023-7205}},
  language     = {{swe}},
  month        = {{07}},
  publisher    = {{Swedish Medical Association}},
  series       = {{Lakartidningen}},
  title        = {{Regional variation i användningen av TTF vid glioblastombehandling}},
  volume       = {{120}},
  year         = {{2023}},
}